Can AI Learn to Smell Disease? A New Dataset Paves the Way
Researchers are developing a large-scale olfactory dataset to train artificial intelligence, potentially unlocking smell as a powerful tool for early disease detection.
Researchers are developing a large-scale olfactory dataset to train artificial intelligence, potentially unlocking smell as a powerful tool for early disease detection.
The high-complexity lab selects Gestalt's PathFlow platform to enhance laboratory workflows and extend capabilities to underserved regions.
Despite powerful advances in precision medicine, most doctors remain untrained in these emerging diagnostic tools.
The system automates cervical cytology with AI-powered sample preparation, imaging, and analysis...
The laboratory reports a 68% increase in one-day turnaround times within weeks of deploying the software platform.
The ethyl alcohol assay categorization enables moderate complexity laboratories to expand drug screening capabilities on the Abbott analyzer platform.
The infrared dye antibody conjugates aim to expand human phenotyping experiments innovation and make high-parameter flow cytometry more accessible.
The DX-60 system offers 28 reportable parameters, malaria detection capabilities, and requires minimal sample volumes for testing.
Market growth driven by expanding clinical applications and regulatory innovation, with kits and reagents dominating product segments.
New instrument features StreamFocus ionization technology and AI-powered intelligence for enhanced sensitivity and efficiency in clinical laboratories.
Research-use-only assay identifies 28 urinary targets and 25 antibiotic resistance markers with same-day turnaround time.
The companies plan to create a fully automated PCR testing system for infectious disease diagnosis and treatment monitoring.
The CLIA-waived immunoassay delivers results in as fast as 10 minutes and is designed for physician offices, urgent care centers, and decentralized hospital labs.
The sharp increase in fentanyl in random drug checks suggests more workers are using the opioid after they have passed pre-employment screens.